文献速递妇产影像泌尿生殖MR

基于MRI影像组学列线图预测晚期高级别浆液性卵巢癌铂类耐药

Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram.
PubMed 文献 · Eur Radiol · 2023-03-30

该多中心回顾性研究纳入301例晚期高级别浆液性卵巢癌患者,从增强T1WI和T2WI全肿瘤提取影像组学特征,构建影像组学列线图。列线图联合影像组学特征与FIGO分期、CA-125、残留肿瘤三个临床特征,预测铂类耐药的AUC为0.799,高于临床模型0.747,并能区分PFS高低风险组。

要点

  • 影像组学列线图预测铂类耐药的AUC为0.799,优于临床模型0.747。
  • 列线图联合影像组学特征与FIGO分期、CA-125、残留肿瘤三个临床特征。
  • 列线图定义的高风险组PFS较短,有助于个体化分层管理。

核心结论

  • 影像组学列线图可识别晚期HGSOC患者的铂类耐药并预测PFS,有助于个体化管理。

研究设计与样本

  • 多中心回顾性研究,纳入301例晚期HGSOC患者。
  • 从增强T1WI和T2WI全肿瘤提取影像组学特征,采用支持向量机递归特征消除法筛选特征。
  • 基于影像组学特征和临床特征通过多变量逻辑回归构建列线图,用ROC分析评估预测性能。

诊断标准与关键数值

  • 影像组学列线图预测铂类耐药的AUC为0.799,临床模型AUC为0.747。
  • NRI和IDI为正值,DCA显示列线图净获益通常高于临床模型和影像组学模型。
  • Kaplan-Meier分析显示列线图定义的高风险组PFS较短。

临床应用与阅片要点

  • 阅片时可关注增强T1WI和T2WI全肿瘤影像组学特征,结合FIGO分期、CA-125和残留肿瘤综合评估铂类耐药风险。
  • 列线图可用于风险分层,高风险组PFS较短,提示需更密切随访或个体化治疗。

局限性

  • 回顾性研究设计。
  • 原文未报告外部验证队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aimed to explore the value of a radiomics nomogram to identify platinum resistance and predict the progression-free survival (PFS) of patients with advanced high-grade serous ovarian carcinoma (HGSOC).

MATERIALS AND METHODS: In this multicenter retrospective study, 301 patients with advanced HGSOC underwent radiomics features extraction from the whole primary tumor on contrast-enhanced T1WI and T2WI. The radiomics features were selected by the support vector machine-based recursive feature elimination method, and then the radiomics signature was generated. Furthermore, a radiomics nomogram was developed using the radiomics signature and clinical characteristics by multivariable logistic regression. The predictive performance was evaluated using receiver operating characteristic analysis. The net reclassification index (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA) were used to compare the clinical utility and benefits of different models.

RESULTS: Five features significantly correlated with platinum resistance were selected to construct the radiomics model. The radiomics nomogram, combining radiomics signatures with three clinical characteristics (FIGO stage, CA-125, and residual tumor), had a higher area under the curve (AUC) compared with the clinical model alone (AUC: 0.799 vs 0.747), with positive NRI and IDI. The net benefit of the radiomics nomogram is typically higher than clinical-only and radiomics-only models. Kaplan-Meier survival analysis showed that the radiomics nomogram-defined high-risk groups had shorter PFS compared with the low-risk groups in patients with advanced HGSOC.

CONCLUSIONS: The radiomics nomogram can identify platinum resistance and predict PFS. It helps make the personalized management of advanced HGSOC.

KEY POINTS: • The radiomics-based approach has the potential to identify platinum resistance and can help make the personalized management of advanced HGSOC. • The radiomics-clinical nomogram showed improved performance compared with either of them alone for predicting platinum-resistant HGSOC. • The proposed nomogram performed well in predicting the PFS time of patients with low-risk and high-risk HGSOC in both training and testing cohorts.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Cai, Deng, et al. Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram. Eur Radiol. 2023. PMID: 36995415. doi:10.1007/s00330-023-09552-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。